Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Inhibikase Therapeutics, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $100 million to support its development of therapeutics for pulmonary arterial hypertension (PAH) [1][5] Group 1: Offering Details - The company is offering 46,091,739 shares of common stock at a price of $1.45 per share and pre-funded warrants at $1.449 each, with a total expected gross proceeds of around $100 million before expenses [1] - An additional 10,344,827 shares may be purchased by underwriters within 30 days at the public offering price [1] - The offering is expected to close on November 24, 2025, subject to customary closing conditions [1] Group 2: Underwriters - Jefferies, BofA Securities, and Cantor are acting as joint book-running managers for the offering [2] - LifeSci Capital and Oppenheimer & Co. are co-lead managers, while H.C. Wainwright & Co. and Ladenburg Thalmann & Co. Inc. are co-managers [2] Group 3: Company Overview - Inhibikase Therapeutics is focused on developing therapeutics for cardiopulmonary diseases, particularly PAH, which affects approximately 50,000 Americans [5] - The lead product candidate is IKT-001, a prodrug of imatinib mesylate, targeting the underlying mechanisms of PAH [5]